Acquisition of Objective Data During Transapical Neochordae Implantation
NCT04709042 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2022-03-24
Summary
Mitral Valve repair (MVr) is the gold standard treatment for primary Mitral Regurgitation. Implantation of artificial Gore-Tex chordae (or neochordae implantation) is often used for MVr.
The NeoChord DS1000 (NeoChord Inc., Minneapolis, USA) is a device designed to deploy neochordae through transapical access in a beating heart and without cardiopulmonary bypass. NeoChord System is CE marked and therefore authorized for use in Europe. Procedure is conducted under 3D transesophageal echocardiography (TEE) guidance. The device is introduced through the apex of the left ventricular (LV) and the prolapsed leaflet is grabbed and harpooned.
The neochordae are thus stretched between the valve and the LV apex. Neochordae length can be precisely adapted to restore a normal coaptation, to treat the regurgitation.
Recently, the principal investigator's teams (heart surgery department at Hospices Civils de Lyon and Laboratoire de Génie Electrique et Ferromagnétique lab at Institut National des Sciences Appliquées (INSA) de Lyon, France) created a platform allowing the measurement of the tension applied on neochordae during a NeoChord procedure. A dedicated protocol was designed and approved by the ethical committee of the French Society of Cardiology. The measurement was performed in 7 patients. This preliminary study shows that the technic is safe. It also suggests that chordal tension might be correlated to the quality of MVr: the sub-valvular apparatus appears to be in a low stress state when the structure and the function of the valve are restored.
These first findings raise new questions:
1. The mechanism involved in the changes in tensions during chordal length adjustment cannot be understood with current standard medical imaging tools. Numerical simulation technologies could bring physical data in order to approach physical phenomenon underlying these findings.
2. Novel chordal tension measurement tools could lead to a change in current paradigm enabling a MVr based on objective data measurement, instead of sole morphological analysis. Prognostic value of chordal tension must be studied through a larger clinical study and a systematic protocol.
A large consortium involving physicians and scientists has been created to address those questions, and a large national funding has been raised to fulfil our objectives over a 4 years period (SIMR project). The present clinical study is the core of this large project.
Conditions
- Mitral Valve Insufficiency
- Mitral Regurgitation
Interventions
- PROCEDURE
-
Chordal tension measurement
The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through "crocodile" clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length.
- OTHER
-
Cardiac Magnetic Resonance Imaging (MRI)
Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Daniel GRINBERG, MD · Hôpital Pneumologique et Cardiovasculaire Louis Pradel
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-01
- Primary Completion
- 2024-05-01
- Completion
- 2024-05-01
More Related Trials
-
ChordArt System for Mitral Regurgitation
NCT03581656 ·Status: UNKNOWN ·Phase: NA
-
European FIH Study - NeoChord Transcatheter Mitral Repair System for Symptomatic Mitral Regurgitation
NCT05425628 ·Status: UNKNOWN ·Phase: NA
-
V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
NCT01415947 ·Status: TERMINATED ·Phase: PHASE2
-
EFS of the CardioMech MVRS
NCT04820764 ·Status: RECRUITING ·Phase: NA
-
A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation
NCT04147884 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System
NCT02703311 ·Status: TERMINATED ·Phase: NA
-
CARDINAL Adjustable Annuloplasty Ring System For Treatment of Mitral Regurgitation
NCT01137734 ·Status: COMPLETED ·Phase: NA
-
Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study
NCT00647387 ·Status: COMPLETED ·Phase: NA
-
Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Following MitraClip
NCT04729933 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluation of Outcomes of CRT and MitraClip for Treatment of Low Ejection Fraction and Functional Mitral Regurgitation in HF
NCT02985268 ·Status: WITHDRAWN ·Phase: NA
-
Clinical Study of NovoClasp for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation
NCT06021509 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A First in Human Study for the Versa Device for Tricuspid Regurgitation
NCT06368401 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study
NCT03929913 ·Status: COMPLETED ·Phase: NA
-
Safety and Performance Study of the Harpoon Mitral Valve Repair System
NCT03285724 ·Status: TERMINATED ·Phase: NA
-
Mi-STITCH™ and Mi-KNOT™ Device Technologies - Improvement of Mitral Valve Repair
NCT05034471 ·Status: UNKNOWN ·Phase: NA
-
The JensClip Transcatheter Valve Repair System for Treating Functional Mitral Regurgitation
NCT05931900 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure
NCT00608140 ·Status: TERMINATED ·Phase: PHASE3
-
Feasibility of the AccuCinch® System for Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function
NCT02153892 ·Status: COMPLETED ·Phase: NA
-
Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation
NCT01920698 ·Status: COMPLETED ·Phase: NA
-
Confirmation Trial of the Acorn CorCap Cardiac Support Device (CSD) at the Same Time as Mitral Valve Repair
NCT00630266 ·Status: UNKNOWN ·Phase: PHASE2
-
Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
NCT01740583 ·Status: UNKNOWN ·Phase: NA
-
Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function
NCT01899573 ·Status: COMPLETED ·Phase: NA
-
Commissural Closure to Treat Severe Mitral Regurgitation: Standing the Test of Time.
NCT05774769 ·Status: COMPLETED
-
Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation
NCT04100720 ·Status: WITHDRAWN ·Phase: NA
-
Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery
NCT03271762 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA